A5023443732- Ovarian cancer diagnosis and treatment
- Cancer Genomics and Diagnostics
- Cancer Mechanisms and Therapy
- Animal Virus Infections Studies
- Cancer-related molecular mechanisms research
- Evolution and Genetic Dynamics
- Gene expression and cancer classification
- Genetic Associations and Epidemiology
- Microtubule and mitosis dynamics
- Genomics and Chromatin Dynamics
- DNA Repair Mechanisms
- Molecular Biology Techniques and Applications
- Hepatocellular Carcinoma Treatment and Prognosis
- Immune cells in cancer
- Reproductive Biology and Fertility
- BRCA gene mutations in cancer
- 14-3-3 protein interactions
- Genomic variations and chromosomal abnormalities
- Cancer Immunotherapy and Biomarkers
- Genomics and Phylogenetic Studies
- Liver physiology and pathology
- Epigenetics and DNA Methylation
- Genetic factors in colorectal cancer
- Immune Cell Function and Interaction
Cancer Research UK
2021-2025
University of Cambridge
2020-2025
MRC Weatherall Institute of Molecular Medicine
2023-2025
University of Oxford
2024-2025
Memorial Sloan Kettering Cancer Center
2025
Cancer Research UK Cambridge Center
2020-2024
Wellcome/MRC Cambridge Stem Cell Institute
2017
Medical Research Council
2017
Abstract The drivers of recurrence and resistance in ovarian high grade serous carcinoma remain unclear. We investigate the acquisition by collecting tumour biopsies from a cohort 276 women with relapsed BriTROC-1 study. Panel sequencing shows close concordance between diagnosis relapse, only four discordant cases. There is also very strong copy number no significant difference purity, ploidy or focal somatic alterations, even when stratified platinum sensitivity prior chemotherapy lines....
Abstract Purpose: Ovarian high-grade serous carcinoma (HGSC) is usually diagnosed at late stage. We investigated whether late-stage HGSC has unique genomic characteristics consistent with acquisition of evolutionary advantage compared early-stage tumors. Experimental Design: performed targeted next-generation sequencing and shallow whole-genome (sWGS) on pretreatment samples from 43 patients FIGO stage I–IIA to investigate somatic mutations copy-number (CN) alterations (SCNA). results 52...
High-grade serous ovarian carcinoma (HGSOC) is the most genomically complex cancer, characterized by ubiquitous
High-grade serous ovarian carcinoma (HGSOC) is characterised by poor outcome and extreme chromosome instability (CIN). Therapies targeting centrosome amplification (CA), a key mediator of missegregation, may have significant clinical utility in HGSOC. However, the prevalence CA HGSOC, its relationship to genomic biomarkers CIN potential impact on therapeutic response not been defined. Using high-throughput multi-regional microscopy 287 HGSOC tissues 73 cell lines models, here we show that...
Abstract Background Mutational processes of diverse origin leave their imprints in the genome during tumour evolution. These are called mutational signatures and they have been characterised for point mutations, structural variants copy number changes. Each signature has an exposure , or abundance, per sample, which indicates how much a process contributed to overall genomic change. not static, better understanding dynamics is key characterise evolution identify cancer cell vulnerabilities...
Abstract Purpose High grade serous carcinoma (HGSC) is the commonest type of ovarian cancer. Nearly all HGSC cases are diagnosed at late stage and it not clear whether early has unique characteristics compared to tumours. Experimental Design We analysed samples from 45 patients with FIGO I - IIA 40 pathology archives three large UK cancer centres 5 BriTROC-1 study. performed shallow whole genome sequencing (sWGS) targeted next generation investigate somatic mutations copy number alterations....
Abstract The drivers of recurrence and resistance in ovarian high grade serous carcinoma (HGSC) remain unclear. We established BriTROC-1 to investigate the acquisition by collecting tumour biopsies from women with recurrent HGSC that had relapsed following at least one line platinum-based chemotherapy. Patients underwent biopsy or secondary debulking surgery, samples fixed methanol-based fixative. Normal DNA tagged-amplicon panel sequencing. Tumour shallow whole genome sequencing (sWGS)....
Abstract Mutational processes of diverse origin leave their imprints in the genome during tumour evolution. These are called mutational signatures and they have been characterised for point mutations, structural variants copy number changes. Each signature has an exposure , or abundance, per sample, which indicates how much a process contributed to overall genomic change. not static, better understanding dynamics is key characterise evolution identify cancer weaknesses that can be exploited...
<title>Abstract</title> Mutational processes of diverse origin leave their imprints in the genome during tumour evolution. These are called mutational signatures and they have been characterised for point mutations, structural variants copy number changes. Each signature has an exposure, or abundance, per sample, which indicates how much a process contributed to overall genomic change. not static, better understanding dynamics is key characterise evolution identify cancer weaknesses that can...
Abstract High grade serous ovarian carcinoma (HGSOC) is characterised by poor outcome and extreme chromosome instability (CIN). Therapies targeting centrosome amplification (CA), a key mediator of missegregation CIN, may have significant clinical utility in HGSOC. However, the prevalence CA HGSOC, its relationship to genomic biomarkers CIN potential impact on therapeutic response not been defined. Using high-throughput multi-regional microscopy 287 HGSOC tumour tissues 73 cancer cell lines,...
Supplementary Figure from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
Supplementary Figure from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
Supplementary Figure from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
Supplementary Figure from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
Supplementary Figure from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
Supplementary Data from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma